Register
Forgot your password?

Chronic heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: pathogenetic parallels, diagnostic challenges and prognostic value

Authors: Smirnova Yu.I.1, Dzhioeva O.N.1 2

Company: 1 National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russian Federation
2 Russian University of Medicine, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2026-20-1-46-57

For citation: Smirnova Yu.I., Dzhioeva O.N. Chronic heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: pathogenetic parallels, diagnostic challenges and prognostic value. Creative Cardiology. 2026; 20 (1): 46–57 (in Russ.). DOI: 10.24022/1997-3187-2026-20-1-46-57

Received / Accepted:  14.01.2026 / 14.01.2026

Keywords: cardiorespiratory comorbidity chronic obstructive pulmonary disease heart failure with preserved ejection fraction diastolic dysfunction biomarkers



Subscribe 🔒

 

Abstract

Chronic heart failure with preserved ejection fraction (HFpEF) is a heterogeneous condition that may develop as a complication of non-cardiac diseases, including chronic obstructive pulmonary disease (COPD). Chronic systemic inflammation contributes to the development of diastolic dysfunction, which partly explains the high prevalence of HFpEF among patients with COPD. In addition, common risk factors and symptoms may lead to underdiagnosis of the COPD-HFpEF comorbidity. A significant worsening of prognosis in patients with COPD-HFpEF phenotype requires close

attention to the problem of cardiorespiratory comorbidity within the medical community.

This literature review outlines the pathogenetic parallels between COPD and HFpEF and summarizes the main principles and approaches to diagnosing this comorbidity. The role of biomarkers, including NT-proBNP, BNP, troponins, galectin-3, and soluble ST2 (sST2), is discussed in detail. Special attention is given to the relationship between COPD and anemia, an important prognostic factor in patients with HFpEF. The findings are presented in the form of a diagnostic algorithm, which, according to the authors, may facilitate diagnostic workup and improve the detection of COPD-HFpEF comorbidity.

References

  1. Galyavich A.S., Tereshchenko S.N., Uskach T.M. et al. 2024 Clinical practice guidelines for chronic heart failure. Russian Journal of Cardiology. 2024; 29 (11): 251–349 (in Russ.). DOI: 10.15829/1560-4071-2024-6162
  2. Chronic obstructive pulmonary disease: guidelines. Ministry of Health of the Russian Federation. 2024 (in Russ.). URL: https://cr.minzdrav.gov.ru/view-cr/603_3 (accessed 25.12.2025).
  3. Eltelbany M., Shah P., de Filippi C. Biomarkers in HFpEF for diagnosis, prognosis, and biological phenotyping. Curr. Heart Fail. Rep. 2022; 19 (6): 412–424. DOI: 10.1007/s11897-022-00578-7
  4. Diab N., Gershon A.S., Sin D.D. et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2018; 198 (9): 1130–1139. DOI: 10.1164/rccm.201804-0621CI
  5. Xu S., Gu Z., Zhu W., Feng S. Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2025; 12 (2): 799–808. DOI: 10.1002/ehf2.14958
  6. Becher P.M., Lindberg F., Benson L. et al. Phenotyping patients with chronic obstructive pulmonary disease and heart failure. ESC Heart Fail. 2025; 12 (2): 900–911. DOI: 10.1002/ehf2.15127
  7. Sandoval-Luna J.A., Rivera-Toquica A., Saldarriaga C. et al. Characteristics, treatment, and prognosis of heart failure patients with chronic obstructive pulmonary disease in the Colombian Heart Failure Registry (RECOLFACA). J. Cardiovasc. Dev. Dis. 2024; 11 (9): 265. DOI: 10.3390/jcdd11090265
  8. Arcoraci V., Squadrito F., Rottura M. et al. Beta-blocker use in older hospitalized patients affected by heart failure and chronic obstructive pulmonary disease: an Italian survey from the REPOSI Register. Front. Cardiovasc. Med. 2022. DOI: 10.3389/fcvm.2022.876693
  9. Martsevich S.Yu., Zakharova N.A., Kutishenko N.P. et al. Clinical practice of beta-blockers usage in patients with cardiovascular and chronic respiratory diseases. Data of outpatient registries PROFILE and RECVASA. Rational Pharmacotherapy in Cardiology. 2017; 13 (4): 469–475 (in Russ.). DOI: 10.20996/1819-6446-2017-13-4-469-475
  10. Shavarova E.K., Babaeva L.A., Padaryan S.S. et al. Chronic heart failure: clinical guidelines and real clinical practice. Rational Pharmacotherapy in Cardiology. 2016; 12 (6): 631–637 (in Russ.). DOI: 10.20996/1819-6446-2016-12-6-631-637
  11. Ayrapetyan A.A., Lazareva N.V., Reytblat O.M. et al. Comorbid conditions in patients with chronic heart failure (according to the registry of chronic heart failure in the Tyumen region). Consilium Medicum. 2023; 25 (10): 685–692 (in Russ.). DOI: 10.26442/20751753.2023.10.202384
  12. Prozorova G.G., Volkorezov I.A., Pashkova O.V. Systemic inflammation and the clinical course of COPD features. Medical Scientific Bulletin of Central Chernozemye. 2009; 37: 34–40 (in Russ.). URL: https://elibrary.ru/kyowdb (accessed 21.12.2025)
  13. Budnevsky A.V., Ovsyannikov E.S., Chernov A.V., Drobysheva E.S. The diagnostic value of systemic inflammation biomarkers in chronic obstructive pulmonary disease. Klinicheskaya Meditsina. 2014; 92 (9): 16–21 (in Russ.). URL: https://elibrary.ru/snhhib (accessed 25.12.2025)
  14. Karnaushkina M.A., Fedosenko S.V., Vinogradov D.L. et al. Chronic obstructive pulmonary disease and cardiovascular diseases: systemic effects. Doktor.ru. 2015; 8–9 (109–110): 50–53 (in Russ.). URL: https://elibrary.ru/vecabl (accessed 25.12.2025)
  15. Ramalho S.H.R., de Albuquerque A.L.P. Chronic obstructive pulmonary disease in heart failure: challenges in diagnosis and treatment for HFpEF and HFrEF. Curr. Heart Fail. Rep. 2024; 21 (3): 163–173. DOI: 10.1007/s11897-024-00660-2
  16. Lee V.V., Timofeeva N.Yu., Zadionchenko V.S. et al. Recent aspects of cardiac remodeling in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2018; 14 (3): 379–386 (in Russ.). DOI: 10.20996/1819-6446-2018-14-3-379-386
  17. Majmundar M., Doshi R., Zala H. et al. Prognostic role of anemia in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Indian Heart J. 2021; 73 (4): 521–523. DOI: 10.1016/j.ihj.2021.06.011
  18. Smirnova M.P., Chizhov P.A., Baranov A.A., Rechkina O.P. Inflammation markers interleukin-6, c-reactive protein and hepcidin in chronic heart failure and iron deficiency patients. Medical Newsletter of Vyatka. 2022; 2 (74): 47–53 (in Russ.). DOI: 10.24412/2220-7880-2022-2-47-53
  19. Levina A.A., Kazyukova T.V., Tsvetaeva N.V. et al. Hepsidin as regulator of iron homeostasis. Pediatria n.a. G.N. Speransky. 2008; 87 (1): 67–74 (in Russ.). URL: https://elibrary.ru/irocsc (accessed 25.12.2025)
  20. Mirghani H., Alshreef A.A., Al-Temani H.A. et al. Updates on the association between anemia and heart failure: a systematic review. Cureus. 2024; 16 (9): e69101. DOI: 10.7759/cureus.69101
  21. Budnevsky A.V., Voronina E.V., Ovsyannikov E.S. et al. Anemia of chronic diseases as a systemic manifestation of chronic pulmonary obstructive disease. Clinical Medicine (Russian Journal). 2017; 95 (3): 201–206 (in Russ.). DOI: 10.18821/0023-2149-2017-95-3-201-206
  22. Tandara L., Grubisic T.Z., Ivan G. et al. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin. Biochem. 2015; 48 (18): 1252–1257. DOI: 10.1016/j.clinbiochem.2015.07.010
  23. Xu Y., Hu T., Ding H., Chen R. Effects of anemia on the survival of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Expert Rev. Respir. Med. 2020; 14 (12): 1267–1277. DOI: 10.1080/17476348.2020.1816468
  24. Klimova A.A., Smolyakova E.V., Ambatello L.G. et al. Possibilities of using a modified questionnaire in patients with broncho-obstructive pathology admitted to a specialized cardiology hospital. Systemic Hypertension. 2025; 22 (1): 35–42 (in Russ.). DOI: 10.38109/2075-082X-2025-1-35-42
  25. Cherniak A.V., Chushkin M.I., Aisanov Z.R. et al. Body plethysmography: national guidelines. Russian Respiratory Society. Russian Association of Specialists in Functional Diagnostics. Pulmonologiya. 2025; 35 (3): 299–330 (in Russ.). DOI: 10.18093/0869-0189-2025-35-3-299-330
  26. Tasha T., Desai A., Bajgain A. et al. A literature review on the coexisting chronic obstructive pulmonary disease and heart failure. Cureus. 2023; 15 (10): e47895. DOI: 10.7759/cureus.47895
  27. Lookzadeh S., Seyyedi S.R., Jamaati H. et al. Relationship between severity of chronic obstructive pulmonary disease and left ventricular diastolic dysfunction. Tanaffos. 2024; 23 (3): 294–299. PMID: 40704342
  28. Mupparapu M., Venkataram R., Baikunje N. et al. Assessment of left ventricular function in subjects with chronic obstructive pulmonary disease. Monaldi Arch. Chest. Dis. 2024; 94 (4). DOI: 10.4081/monaldi.2023.2654
  29. Bhattacharjee R., Deb T., Roy P. et al. Echocardiographic evidence of left ventricular dysfunction in COPD: relationship with disease severity. Medicina (Kaunas). 2025; 61 (7): 1260. DOI: 10.3390/medicina61071260
  30. Farouk H., Albasmi M., El Chilali K. et al. Left ventricular diastolic dysfunction in patients with chronic obstructive pulmonary disease: impact of methods of assessment. Echocardiography. 2017; 34 (3): 359–364. DOI: 10.1111/echo.13469
  31. Abdo M., Watz H., Alter P. et al. Characterization and mortality risk of impaired left ventricular filling in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2025; 211 (3): 477–485. DOI: 10.1164/rccm.202310-1848OC
  32. Liu C.Y., Heckbert S.R., Lai S. et al. Association of elevated NT-proBNP with myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 2017; 70 (25): 3102–3109. DOI: 10.1016/j.jacc.2017.10.044
  33. Su X., Lei T., Yu H. et al. NT-proBNP in different patient groups of COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2023; 18: 811–825. DOI: 10.2147/COPD.S396663
  34. Hawkins N.M., Khosla A., Virani S.A. et al. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm. Med. 2017; 17 (1): 11. DOI: 10.1186/s12890-016-0345-7
  35. Høiseth A.D., Omland T., Hagve T.A. et al. NT-proBNP independently predicts long term mortality after acute exacerbation of COPD – a prospective cohort study. Respir. Res. 2012; 13 (1): 97. DOI: 10.1186/1465-9921-13-97
  36. Elmenawi K.A., Anil V., Gosal H. et al. The importance of measuring troponin in chronic obstructive pulmonary disease exacerbations: a systematic review. Cureus. 2021; 13 (8): e17451. DOI: 10.7759/cureus.17451
  37. Kallis C., Kaura A., Samuel N.A. et al. The relationship between cardiac troponin in people hospitalised for exacerbation of COPD and Major Adverse Cardiac Events (MACE) and COPD readmissions. Int. J. Chron. Obstruct. Pulmon. Dis. 2023; 18: 2405–2416. DOI: 10.2147/COPD.S432166
  38. Cockell N., Billing N., Kumareshan P., Nagarajan T. Does a raised serum troponin during a severe chronic obstructive pulmonary disease exacerbation predict future cardiovascular events? Cureus. 2025; 17 (2): e79288. DOI: 10.7759/cureus.79288
  39. Drapkina O.M., Deeva T.A. Galectin-3 – biomarker of fibrosis in patients with metabolic syndrome. Russian Journal of Cardiology. 2015; 20 (9): 96–102 (in Russ.). DOI: 10.15829/1560-4071-2015-09-96-102
  40. Shi Y., Liu J., Liu C. et al. Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Front. Cardiovasc. Med. 2022; 9: 937291. DOI: 10.3389/fcvm.2022.937291
  41. Vergaro G., Aimo A., Januzzi J.L. Jr. et al. Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. J. Cardiovasc. Med. 2022; 23 (1): 28–36. DOI: 10.2459/JCM.0000000000001281

About Authors

  • Yuliya I. Smirnova, Resident Physician; ORCID
  • Olga N. Dzhioeva, Dr. Med. Sci., Leading Researcher, Director of Institute of Professional Education, Head of Laboratory of Cardioimaging, Autonomic Regulation and Somnology; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by